Logo

Centus Biotherapeutics' Equidacent (bevacizumab- biosimilar) Receives CHMP's Positive Opinion for the Treatment of Multiple Cancer Indications

Share this

Centus Biotherapeutics' Equidacent (bevacizumab- biosimilar) Receives CHMP's Positive Opinion for the Treatment of Multiple Cancer Indications

Shots:

  • The EMA’s CHMP has adopted a positive opinion recommending the MAA of Centus’ Equidacent (bevacizumab)- a biosimilar to Roche's Avastin to treat carcinoma of the colon or rectum- breast cancer- NSCLC- RCC- epithelial ovarian- fallopian tube or primary peritoneal cancer- and carcinoma of the cervix
  • Equidacent will be available as 25 mg/ml as the solution for infusion targeting VEGF and act by inhibiting the binding of VEGF to its receptors on endothelial cell
  • The company anticipates EC’s decision in ~60days. The clinical data demonstrated that Equidacent has comparable quality- safety- and efficacy to Avastin

  Ref: PRNewswire | Image: PharmaShots

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions